Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efsubaglutide α
- Development stage
- Unknown
- Lead developer
- Shanghai Benemae Pharmaceutical
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Efsubaglutide α (BEM-059) is a long-acting recombinant human glucagon-like peptide-1 (GLP-1) receptor agonist. It is a fusion protein consisting of a GLP-1 analogue fused to the Fc portion of human IgG4, designed for once-weekly subcutaneous administration. Developed by Shanghai Benemae Pharmaceutical, it is being investigated for the treatment of type 2 diabetes mellitus, obesity, and polycystic ovary syndrome (PCOS). By activating the GLP-1 receptor, it enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to improved glycemic control and weight loss. Clinical studies have evaluated its efficacy both as a monotherapy and in combination with lifestyle interventions such as high-dose dietary fiber.
- Other names
- efsubaglutide alphaefsubaglutide艾夫糖肽α
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)GLP1R (GLP-1R)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on efsubaglutide α.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efsubaglutide α.